Safety and effectiveness of tenofovir alafenamide in the Turkish population: A systematic review

Basit Öğe Kaydı
dc.contributor.authorTabak, Fehmi
dc.contributor.authorYapalı, Suna
dc.contributor.authorÇelen, Mustafa Kemal
dc.contributor.authorGüner, Rahmet
dc.date.accessioned2024-04-24T17:24:33Z
dc.date.available2024-04-24T17:24:33Z
dc.date.issued2023
dc.departmentDicle Üniversitesien_US
dc.description.abstractHepatitis B virus infection is an important public health problem in the world and in Turkey. Nucleoside analogues and pegylated interferon-alpha are used as therapeutic agents in the management of chronic hepatitis B (CHB) infection. With current treatments, the disease is at a controllable point. Unfortunately, although cure studies continue, the cure treatments in the near future will not be an alternative. Tenofovir disoproxil fumarate (TDF) has been used for the treatment of CHB infection since 2008. Beside its high antiviral activity and lack of resistance, long-term use of TDF may lead to a decline in renal functions and bone mineral density. As a prodrug, tenofovir alafamide (TAF) provides considerable reduction (%90) in systemic exposure to tenofovir and has a better safety profile. TAF was used in some special cases (osteoporosis and decreased renal functions) in Turkey. In 2020, TAF was reimbursed for naive and treatment-experienced patients CHB patients. Evidence for the efficacy and safety of TAF continues to accumulate at an accelerating rate, especially following removal of reimbursement restrictions in 2020. In this review, we aim to summarize the real-world evidence obtained about TAF treatment in the last two years in Turkey.en_US
dc.identifier.citationTabak, F., Yapalı, S., Çelen, M. K. ve Güner, R. (2023). Safety and effectiveness of tenofovir alafenamide in the Turkish population: A systematic review. Viral Hepatitis Journal, 29(2), 43-51.
dc.identifier.doi10.4274/vhd.galenos.2023.2023-8-3
dc.identifier.endpage51en_US
dc.identifier.issn1307-9441
dc.identifier.issn2147-2939
dc.identifier.issue2en_US
dc.identifier.startpage43en_US
dc.identifier.urihttps://doi.org/10.4274/vhd.galenos.2023.2023-8-3
dc.identifier.urihttps://hdl.handle.net/11468/19731
dc.identifier.volume29en_US
dc.identifier.wosWOS:001080086800002
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.language.isoenen_US
dc.publisherGalenos Publ Houseen_US
dc.relation.ispartofViral Hepatit Dergisi-Viral Hepatitis Journal
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectChronic Hbv infectionen_US
dc.subjectEfficacyen_US
dc.subjectTenofovir alafenamideen_US
dc.titleSafety and effectiveness of tenofovir alafenamide in the Turkish population: A systematic reviewen_US
dc.titleSafety and effectiveness of tenofovir alafenamide in the Turkish population: A systematic review
dc.typeReview Articleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Safety and Effectiveness of Tenofovir Alafenamide in the Turkish PopulationA Systematic Review.pdf
Boyut:
323.74 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Makale Dosyası
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu